Pharma BD Deal Intelligence
Lilly's $1.4B all-cash acquisition of POINT Biopharma bought a radioligand-therapy platform and Indianapolis manufacturing footprint, not a single asset—now the deciding factor, since lead prostate-cancer candidate PNT2002 missed on overall survival and partner Lantheus walked away from an NDA in May 2025.
Lilly acquired Point Biopharma for $1.4B for radiopharmaceuticals.
Lilly to acquire POINT Biopharma for $1.4B to expand into next-gen radioligand therapies.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Eli Lilly acquired POINT Biopharma Global in an all-cash tender offer at $12.50 per share (~$1.4 billion), announced October 3, 2023 and completed December 27, 2023, to build an in-house radioligand therapy (RLT) capability. Lilly's stated rationale centered on POINT's radiopharmaceutical PLATFORM and its ~180,000-sq-ft Indianapolis manufacturing campus rather than any single asset. POINT's lead clinical program, PNT2002 (177Lu-PSMA-I&T) for metastatic castration-resistant prostate cancer, met its Phase 3 SPLASH primary endpoint (median rPFS 9.5 vs 6.0 months) but the final overall-survival analysis was confounded by an ~85% control-arm crossover and did not favor the drug; Lantheus -- which held ex-territory commercial rights under a November 2022 license ($260M upfront, up to ~$1.8B milestones) -- said on May 7, 2025 it would not pursue an NDA or further invest in PNT2002. The second program, PNT2003 (no-carrier-added Lu-177 dotatate, a LUTATHERA radioequivalent for GEP-NETs), received FDA tentative ANDA approval on March 2, 2026, with full approval gated on a 30-month Hatch-Waxman stay expiring June 2026. Net: Lilly's radiopharma entry remains intact via the platform and manufacturing, but the lead prostate-cancer asset that anchored the original headlines has effectively been abandoned.
310K US cases/yr · $4.4B US mCRPC Market (2023) · $2.1B Novartis Pluvicto+Lutathera Revenue (2024)
Radioligand therapy (RLT) delivers targeted radiation directly to cancer cells by linking a radioisotope to a molecule that binds tumor-specific antigens like PSMA. This enables potent anti-tumor efficacy while limiting damage to healthy tissue. The prostate cancer segment dominates RLT (~55% market share), with mCRPC as the primary indication. Lilly's acquisition of POINT brought clinical programs, manufacturing infrastructure, and supply-chain expertise in isotope sourcing.
POINT's lead asset PNT2002 targets PSMA in mCRPC, competing with Novartis's Pluvicto (lutetium-177 PSMA-617). The acquisition included a manufacturing campus in Indianapolis and supply chain know-how critical for isotope sourcing, a major industry bottleneck. Lilly completed the $1.4B acquisition in December 2023.
Eli Lilly completed $1.4B acquisition of Point Biopharma, gaining PNT2002 next-gen PSMA radioligand for mCRPC.
Lilly continued Point's PSMA radioligand development, building radiopharmaceutical manufacturing to compete with Novartis Pluvicto.
Lantheus (ex-territory rights holder) reports SPLASH reached 100% of OS events, still confounded by ~85% crossover, and will not pursue an NDA or further invest in PNT2002 (177Lu-PSMA mCRPC).
FDA grants tentative ANDA approval for Lu-177 dotatate (PNT2003), a LUTATHERA radioequivalent for GEP-NETs; full approval gated on 30-month Hatch-Waxman stay expiring June 2026.
Point gives Lilly competitive PSMA radioligand and manufacturing capabilities. Advancing but behind Novartis Pluvicto in timeline.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Point Biopharma (this deal) | 2023 | $1.4B | 62 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2023 deals · Eli Lilly and Company deals · Neurology deals